Souhaitez-vous accéder aux communiqués récents ?

Aeroflow’s Comprehensive Diabetes Management Program is built to streamline the diabetes management process for both patients and providers.

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe trial is expected to enroll 250 patients to receive treatment over 36 weeks...

Vantage Biosciences, a clinical-stage biotechnology company advancing innovative therapies for diabetic eye diseases, announces first NPDR patient dosed.

UMeWorld launches innovation hub, names Chief Scientist, and accelerates global rollout of heart-healthy DAGola oil with 80% less triglycerides.

Teladoc Health's new offering is designed to support optimal cardiometabolic health for all populations and prevent the progression of disease.

MANNKIND TEAMS UP WITH JUNCOS HOLLINGER RACING (JHR) DRIVER CONOR DALY TO DRIVE AWARENESS OF DIABETES AND INNOVATIVE TREATMENT OPTIONS

The FITTER Forward Expert Recommendations are an updated set of global best practices for insulin injection technique and education.

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Needle Free Diabetes Care Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption...

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22